Benzinga's Top #PreMarket Losers

shares dropped 8.59 percent to $84.50 in pre-market after the company reported updated Phase 2 results from two ongoing clinical studies with rucaparib: ARIEL2 and Study 10.

shares declined 1.14 percent to $86.15 in pre-market trading. Raymond James downgraded Express Scripts Holding from Outperform to Market Perform.

fell 0.88 percent to $124.59 in pre-market trading. Citigroup downgraded F5 Networks from Buy to Neutral and raised the price target from $122.00 to $132.00.

shares fell 0.87 percent to $38.69 in pre-market trading after dropping 0.38 percent on Friday.

shares tumbled 0.65 percent to $50.77 in pre-market trading after falling 0.35 percent on Friday.